- Stocks
- Healthcare
- NASDAQ: TOI

Price (delayed)

$0.5277

Market cap

$39.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.81

Enterprise value

$123.06M

TOI's revenue is up by 25% year-on-year and by 6% since the previous quarter

The EPS has plunged by 50% YoY but it has grown by 12% from the previous quarter

Oncology Institute's net income has decreased by 17% YoY but it has increased by 15% QoQ

TOI's equity has dropped by 58% year-on-year and by 28% since the previous quarter

The quick ratio has contracted by 25% from the previous quarter and by 19% YoY

Sector: Healthcare

Industry: Medical Care Facilities

What are the main financial stats of TOI

Market
Valuations
Earnings

Shares outstanding

74.44M

Market cap

$39.28M

Enterprise value

$123.06M

Price to earnings (P/E)

N/A

Price to book (P/B)

0.95

Price to sales (P/S)

0.11

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.36

Revenue

$342.71M

EBIT

-$51.74M

EBITDA

-$45.64M

Free cash flow

-$40.08M

Per share
Balance sheet
Liquidity

EPS

-$0.81

Free cash flow per share

-$0.54

Book value per share

$0.56

Revenue per share

$4.62

TBVPS

$2.43

Total assets

$204.53M

Total liabilities

$163.24M

Debt

$119.84M

Equity

$41.3M

Working capital

$95.42M

Debt to equity

2.9

Current ratio

3.08

Quick ratio

2.73

Net debt/EBITDA

-1.84

Margins
Efficiency
Dividend

EBITDA margin

-13.3%

Gross margin

16.8%

Net margin

-16.9%

Operating margin

-18.1%

Return on assets

-26.8%

Return on equity

-90.7%

Return on invested capital

-21.5%

Return on capital employed

-32.6%

Return on sales

-15.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Oncology Institute stock price performed over time

Intraday

1.48%

1 week

5.54%

1 month

19.93%

1 year

-41.7%

YTD

-74.13%

QTD

14.72%

How have Oncology Institute's revenue and profit performed over time

Revenue

$342.71M

Gross profit

$57.44M

Operating income

-$62.12M

Net income

-$57.77M

Gross margin

16.8%

Net margin

-16.9%

Oncology Institute's operating margin has increased by 49% YoY and by 24% from the previous quarter

The operating income rose by 36% year-on-year and by 19% since the previous quarter

TOI's revenue is up by 25% year-on-year and by 6% since the previous quarter

The company's net margin rose by 19% QoQ and by 6% YoY

What is Oncology Institute's growth rate over time

What is Oncology Institute stock price valuation

P/E

N/A

P/B

0.95

P/S

0.11

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.36

The EPS has plunged by 50% YoY but it has grown by 12% from the previous quarter

TOI's equity has dropped by 58% year-on-year and by 28% since the previous quarter

The stock's P/B is 47% less than its last 4 quarters average of 1.8

The P/S is 63% less than the last 4 quarters average of 0.3

TOI's revenue is up by 25% year-on-year and by 6% since the previous quarter

How efficient is Oncology Institute business performance

The company's return on equity has shrunk by 118% YoY and by 4.3% QoQ

The ROA is down by 32% year-on-year but it is up by 12% since the previous quarter

The ROS has grown by 20% from the previous quarter and by 6% YoY

The company's return on invested capital rose by 10% QoQ but it fell by 5% YoY

What is TOI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for TOI.

How did Oncology Institute financials performed over time

The total assets is 25% more than the total liabilities

The current ratio has contracted by 25% from the previous quarter and by 22% YoY

The quick ratio has contracted by 25% from the previous quarter and by 19% YoY

The company's debt is 190% higher than its equity

The debt to equity has soared by 159% YoY and by 38% from the previous quarter

TOI's equity has dropped by 58% year-on-year and by 28% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.